Chapter 32: Lung Cancer

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

So 25 % of all lung cancer patients have absolutely zero symptoms of diagnosis.

Right, none at all.

And another 25%.

They have actually never touched a cigarette in their entire lives.

Yeah, those numbers completely shattered that classic clinical stereotype.

I mean, you walk into the exam room as a student expecting a decades long heavy smoker with a chronic hacking cough, but half the time that is just not the patient sitting in front of you.

Which is exactly why we are dedicating this deep dive to really mastering the clinical reality of lung cancer.

If you're an advanced practice nursing student, you know lung cancer care costs the U .S.

over $13 billion annually.

Oh yeah, it's massive.

And it remains the leading cause of cancer deaths.

So our mission today is to cut through all the noise.

We're gonna give you the foundational pathophysiology, the assessment strategies and the management plans you need to actually catch this disease and manage it safely in primary care.

Absolutely.

And to build that clinical suspicion, we have to start with the who and the why.

So new cases and lung cancer deaths peak in adults aged 55 to 65.

Right, but the disparities there stand out immediately, don't they?

They really do.

Black men are 30 % more likely to have lung cancer than white men, and that's even though statistically black men smoke less.

Yeah, and we're also seeing this really troubling rise in female mortality.

Women appear to be more susceptible to the carcinogenic effects of tobacco smoke than men are.

Meaning the exact same amount of exposure causes significantly more cellular damage in women.

Exactly, and smoking obviously drives the majority of these cases.

The risk scales up based on duration, how early they started, and if they use high tar cigarettes.

But the environmental and occupational multipliers are just massive.

It's like secondhand smoke.

Right, environmental tobacco smoke increases the risk of dying from lung cancer by 30%.

And radon gas, people forget about radon, it silently kills almost 3 ,000 nonsmokers annually.

Wow.

Yeah, and get this.

If you have a patient who smokes and is also exposed to asbestos, their risk doesn't just add together.

It multiplies by a staggering factor of 92.

Wait, 92 times?

A factor of 92, it's incredible.

That is wild.

But I really wanna pause on that nonsmoker demographic for a second, because patients who have never smoked face a dismal five -year survival rate of just 1%.

Yeah, it's a really heartbreaking statistic.

But logically, if a patient doesn't have the compounding global lung damage of chronic smoking,

their immune system and their overall pulmonary reserve should be way stronger, right?

Mechanistically, they should be fighting the tumor better.

So why is that survival rate almost non -existent?

Well, the low survival rate in nonsmokers, it isn't driven by tumor biology.

It's actually driven by anchoring bias from us, from healthcare providers.

Oh, wow.

Yeah, think about it.

When a 50 -year -old nonsmoker presents to your clinic with like a lingering cough or mild fatigue, your brain naturally anchors to common benign causes.

Right, you suspect post -nasal drip or allergies or just a really stubborn bronchitis.

Cancer simply isn't on the differential.

And because of that lack of clinical suspicion, early stage diagnosis is severely delayed.

By the time the tumor grows large enough to cause undeniable severe symptoms, it is usually already metastasized.

Man, that anchoring bias is dangerous.

It really means we have to intimately understand what is happening at the cellular level so we know exactly what clinical clues to look for early on.

Yes, exactly.

So when those toxins, whether they're from active smoking or radon or asbestos when they enter the lungs,

what is the exact mechanism of injury?

So the toxins don't just distribute evenly across the lung tissue.

They preferentially deposit right at the bifurcations of the bronchial wall.

Okay, because every time the airway branches, the airflow becomes turbulent.

You got it.

The turbulence causes those heavy particulates to crash directly into the respiratory epithelium right at those junctions.

And this chronic bombardment alters mucus production and just continuously injures the cells.

And that chronic injury eventually breaks down the cellular defenses,

specifically the P53 tumor suppressor gene.

Yes, the famous P53 gene.

Often called the guardian of the genome because its entire job is to trigger apoptosis, programmed cell death in damaged cells before they can even replicate.

Right, but in about 60 % of all non -small cell lung cancers,

that P53 gene mutates and completely fails.

And once that guardian falls,

the normal ciliated cells lining the airway get rapidly replaced by this chaotic proliferation of basal cells.

Yeah, it follows a very predictable cellular cascade.

It goes from simple hyperplasia to dysplasia, then to carcinoma in situ, and finally it breaks through the basement membrane to become a true invasive carcinoma.

And clinical guidelines divide these invasive carcinomas into two main categories, right?

Small cell lung cancer,

or SCLC,

and non -small cell lung cancer, NSCLC.

Correct, so let's talk about small cell first.

It accounts for about 15 to 20 % of cases.

It originates centrally deep in the submucosa of the airways and it is notoriously aggressive.

Right, and the reason SCLC is so aggressive really comes down to its anatomical origin.

Because it develops in the submucosa, it's practically sitting right on top of a major highway on -ramp to the lymphatic system and the blood vessels.

Exactly, it doesn't have to grow very large at all before it gains immediate access to systemic circulation, which is why early distant metastasis is its absolute hallmark.

And there are three types of SCLC, right?

Oat cell, intermediate, and combined.

Yep, and they all share that same rapid systemic spread.

Okay, so if SCLC is like this central factory pumping cancer cells directly into the vascular highway, the other 85 % of cases, the non -small cell lung cancers, they must have vastly different growth patterns depending on where they originate.

They do, and understanding these subtypes directly predicts what you'll see on an X -ray or CT scan.

So within an SCLC, you have squamous cell carcinoma.

That one also clusters centrally in the main stem bronchi.

But it's slow growing, right?

Right, slow growing originates from epithelial cells and it often produces a skin protein called keratin.

Then you have adenocarcinoma.

This is the most common type of lung cancer in non -smokers and in women.

And unlike the central tumors,

adenocarcinoma grows way out in the far periphery of the lungs.

It forms these glandular structures rather than squamous layers.

Exactly, and finally there's large cell carcinoma.

That one forms bulky necrotic masses.

It grows rapidly and has this bizarre predilection for metastasizing specifically to the small intestine.

Wow, the small intestine.

Yeah, it's very specific.

But the physical location of these tumors, whether they're sitting centrally in a main bronchus or out in the peripheral lung tissue that dictates the entire clinical presentation.

Makes sense.

A peripheral adenocarcinoma can basically grow silently in the expansive space of the lung edges, whereas a central squamous cell or small cell tumor is going to irritate the major airways almost immediately.

Exactly, that structural reality is why intra -thoracic symptoms present the way they do.

A cough is present in 60 to 75 % of patients simply because the tumor is physically irritating the bronchial mucosa.

You'll also see dyspnea or hemoptysis, coughing up blood, which happens when a tumor erodes into the highly vascular airway lining, and that's an event much more common in NSCLC.

Right, and there is also a very specific type of wheezing to listen for during your assessment.

Oh, the monophonic wheeze.

Yes,

if you auscultate a wheeze that is monophonic, meaning it's just a single continuous pitch and it's highly localized to one specific area and it does not clear when the patient coughs, that indicates a fixed mechanical obstruction.

Because the air is literally whistling past a rigid tumor mass, it's not just moving through reversible bronchospasm.

Exactly, but because peripheral tumors like adenocarcinoma grow silently, they often aren't caught until they expand into critical neighboring structures.

And when that happens, you start seeing those distinct red flag physical exam findings that tell you the tumor is likely non -resectable.

Right, for instance, a patient might present with severe hoarseness.

This occurs because the tumor has invaded the mediastinum and is physically compressing the recurrent laryngeal nerve, which paralyzes the vocal cord.

Another major red flag is superior vena cava syndrome.

The tumor mass compresses the SVC, blocking all that venous blood flow returning from the head and upper body.

Which results in really severe facial and upper extremity edema.

We also have to assess for Horner syndrome.

Right, that presents as unilateral pretosis, so a drooping eyelid meiosis, which is a constricted pupil, and anadrosis, so a total lack of sweating on just that one side of the face.

Yeah, Horner syndrome is a classic example of structural invasion.

The tumor is invading the cervical sympathetic nerve plexus at the top of the chest,

effectively severing the sympathetic nervous system's control over that side of the face.

That's fascinating.

Similarly, Panko syndrome occurs when a tumor at the extreme apex of the lung invades the brachial plexus.

So instead of typical respiratory symptoms, they get severe arm and shoulder pain.

Exactly, but beyond structural compression, the pathophysiology gets even more complex with perineoplastic syndrome.

Right, where the tumor essentially goes rogue.

Perfect way to put it.

Through a process of cellular de -differentiation, the mutated cancer cells revert to this primitive state.

They accidentally turn on genes that produce hormones, they have absolutely no business making.

The lung tumor basically acts like an ectopic endocrine gland.

And small cell lung cancer is highly notorious for this, isn't it?

Oh, very.

It can turn on the production of ectopic ACTH, which floods the body with cortisol and causes Cushing's syndrome.

It can also start secreting antidiuretic hormone, leading to SIADH.

That causes the kidneys to aggressively retain water, resulting in really dangerous water intoxication and severe hyponadremia.

Right.

It can even trigger an autoimmune response known as Lambert -Eton -Myasthenic syndrome, where antibodies attack calcium channels, impairing acetylcholine release and causing profound proximal muscle weakness.

Wow.

Meanwhile, non -small cell lung cancers are heavily associated with humoral hypercalcemia.

Yes.

The tumor secretes a parathyroid hormone -related protein that literally leeches calcium out of the bones and into the blood.

But bringing this all back to the daily reality of advanced practice nursing,

how do you differentiate the baseline chronic smoker's cough of a patient with COPD from a new insidious tumor cough?

I mean, both involve chronic airway irritability.

It's a great question.

You really have to interrogate the history for a distinct change in the pattern.

A COPD cough is fairly consistent for that individual patient.

You are looking for a change in the pitch or the character of the cough.

Or a change in the quantity, quality, or color of the sputum.

Exactly.

And most importantly, you are looking for a sudden lack of response to standard therapies.

If you prescribe bronchodilators or antibiotics for what you think is a standard exacerbation and their respiratory symptoms do not improve at all, your clinical suspicion for a structural lesion needs to spike immediately.

And once that suspicion spikes,

your diagnostic workup needs to be methodical.

You start with foundational labs.

A CBC to check for underlying anemia and a CMP.

And with that CMP, you're paying very close attention to the sodium and calcium levels to catch those perineoplastic syndromes you just broke down.

Right, you also need a PTPTT to assess for coagulopathies before you even plan any tissue biopsies.

Yeah.

For initial imaging, a standard chest X -ray is the typical first step, but it has severe limitations.

An X -ray requires a tissue nodule to be at least two to three millimeters dense to even cast a visible shadow.

So it might catch a large obvious mass, but it will easily miss early diffuse or hidden lesions.

Precisely.

Because of that limitation, a contrast enhanced chest CT is the primary cross -sectional imaging modality for evaluating the thorax and staging NSCLC.

Because the contrast helps differentiate vascular structures from lymph nodes and tumor masses, right?

Right.

And crucially, this CT scan must extend inferiorly to include the liver and the adrenal glands.

Those organs are highly common sites for early silent metastasis.

And catching that spread immediately changes the entire staging.

But imaging only gives us a shadow, right?

We need actual tissue to prove the cell type.

We do.

And the physical location of the tumor on that CT scan dictates how we get that tissue.

If it's a central lesion sitting the main airways, flexible fiber optic bronchoscopy is the standard approach.

It allows direct visualization and biopsy.

But if it's a peripheral lesion near the chest wall,

a percutaneous fine needle aspiration,

or FNA guided by CT, is much safer and more accurate.

Right.

Now mechanistically, sputum cytology is limited by tumor location.

It has an almost 100 % positive predictive value, meaning if you see malignant cells under the microscope, the patient absolutely has cancer.

However, its overall sensitivity is only about 10 to 15%.

It really only works if a large central tumor is actively shedding cells into the major airways where they could be coughed up.

Exactly.

For a peripheral adenocarcinoma, sputum cytology is essentially useless.

Good to know.

So once we secure the TICU and confirm the histology, we have to stage the disease.

For NSCLC, clinical guidelines utilize the eighth edition TNM system.

Right, which evaluates the size and local invasion of the primary tumor, the extent of regional nodal involvement, and the presence of distant metastasis.

But small cell lung cancer requires a completely different staging approach, doesn't it?

It does.

Because SCLC is that fast moving submucosal factory with early access to the vascular highway, it doesn't fit neatly into the TNM progression.

By its very nature, it has usually already spread microscopically.

So it's broadly classified into just two categories.

Right, limited stage disease, meaning the cancer is confined to one hemothorax and can be safely targeted within a single radiation port, and extensive stage disease where it has spread beyond those boundaries.

Now, knowing that this cancer has a high propensity to metastasize to the brain and the bones, it feels almost negligent not to order a head CT and a full bone scan for every single patient at the time of diagnosis, just to be safe.

I know, and that is a very common trap.

But advanced practice nursing requires adherence to high value evidence -based care.

Routine indiscriminate scanning exposes the patient to unnecessary radiation, high costs, and the psychological burden of false positives.

Right, so what do the guidelines say?

They explicitly state that you only order a head CT or brain MRI if the patient demonstrates actual neurologic signs or symptoms of central nervous system disease.

And you only order a bone scan if the patient complains of localized bone pain, or if their lab work reveals an unexplained elevation in calcium or alkaline phosphatase.

Exactly, we let the clinical assessment drive the technology, not the other way around.

I love that.

So with the staging complete, the focus shifts to a safe, patient -centered management plan.

But true management actually begins long before the diagnosis, leading heavily into prevention and screening.

Yes, the U .S.

Preventive Services Task Force recommends annual screening with low -dose CT or LDCT.

And this is targeted at adults aged 55 to 80 who have at least a 30 -pack year smoking history, and who either currently smoke or have quit within the past 15 years.

Right, identifying a tumor at stage I or two through that screening is the patient's only realistic chance for a surgical cure.

When surgery is viable, a lobectomy is the most common procedure, right?

Removing the entire affected lobe to ensure clean margins while preserving as much respiratory function as possible.

Yep.

If the tumor has invaded proximal structures, a pneumonectomy, the removal of the entire lung might be necessary.

However, surgeons can sometimes perform a sleeve resection.

Oh, where they physically cut out the diseased section of the bronchus and reattach the healthy ends, thereby sparing the surrounding lung parenchyma.

Exactly.

Conversely, if a patient has extremely poor pulmonary reserve and cannot tolerate losing a full lobe, they might only undergo a limited wedge resection or segmentectomy.

But the difficult reality is that fewer than half of all lung cancer patients are viable surgical candidates at diagnosis.

Yeah.

For stage III and SCLC, and for almost all cases of SCLC, management relies entirely on systemic chemotherapy and radiation.

We are also utilizing targeted therapies based on the tumor's genetic profile.

Like Pembrolizumab, which is a PD -1 inhibitor that prevents cancer cells from hiding from the immune system, and Bivacizumab, an angiogenesis inhibitor that starves the tumor by preventing it from forming new blood vessels.

Exactly, and for SCLC specifically, the standard of care for limited stage diseases combining thoracic radiation directly with chemotherapy,

they also routinely administer prophylactic cranial irradiation.

Wait, even if the initial brain scans are totally clear?

Yes.

They radiate the brain simply to destroy any microscopic metastases that have likely already crossed the blood -brain barrier.

Wow.

Which really forces us to have a very difficult conversation about goals of care.

When a patient sits in your office with stage four metastatic disease, you must ground both yourself and the patient in reality.

You do.

For advanced disease, chemotherapy is non -curative.

It provides marginal survival benefits, but the fundamental priority of care shifts.

The focus becomes symptom palliation,

maintaining the highest possible quality of life, and aggressively respecting the patient's autonomy.

Right.

You are treating complications and slowing tumor growth, but above all, your primary medical directive is the relief of suffering.

And that holistic perspective extends into long -term follow -up for patients who do undergo curative treatment.

The protocol requires a thorough history and physical every three months for the first two years, and then every six months through year five.

But again, adhering to high -value care, we do not order routine CT scans or lab work in asymptomatic patients.

A simple yearly chest x -ray is sufficient to evaluate for a second primary cancer without subjecting them to cumulative radiation toxicity.

And your role in health promotion is equally critical.

Smoking cessation must be addressed at every single visit.

Absolutely.

The evidence demonstrates that the most effective strategy is a multimodal approach.

Combining a tapering nicotine patch to manage the physical withdrawal with dedicated behavioral interventions to rewrite the psychological habits.

Yeah.

And as the disease progresses toward its end stages, your interprofessional collaboration skills really take center stage.

Transitioning a patient to hospice care is a vital clinical intervention, not a failure.

Right.

Many states now utilize an open access model, which is incredibly beneficial because it allows a patient to continue receiving certain life prolonging or palliative treatments like targeted radiation for severe bone pain, while simultaneously accessing comprehensive hospice services.

Frameworks like the Circle of Caring model help you guide families through this transition, enabling them to make informed choices and truly live in the moments they have left.

Such an important framework.

It really is.

And as we conclude this deep dive, I want you to think critically about the societal environment surrounding this disease.

Consider the profound stigma attached to lung cancer across the board.

Because society largely views it as a self -inflicted condition, right?

Right.

There is an immense unspoken shame placed on these patients.

So how much does that stigma alter the clinical timeline?

Are patients minimizing a worsening cough or hiding hemoptysis because they are terrified of being blamed by their own healthcare providers?

That's a powerful point.

If the fear of a lecture keeps them out of your clinic during stage I, the stigma itself becomes just as lethal as the tumor.

Your assessment environment must be totally free of judgment or you will never catch this disease in time.

Exactly.

Well, thank you for joining us for this deep dive.

Keep asking great questions.

Keep caring for your patients and a warm thank you from the last minute lecture team.

See you next time.